

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <a href="https://www.bccancer.bc.ca">www.bccancer.bc.ca</a> and according to acceptable standards of care

## PROTOCOL CODE: MYDARLD (subcut)

(Page 1 of 4)

	Patient RevAid #				
DOCTOR'S ORDERS	Ht	_cm	Wt	kg	BSAm²
REMINDER: Please ensure drug allerg	ies and previous bled	myc	in are de	ocumented	on the Allergy & Alert Form
DATE:	To be given:			Cycle	e #:
Date of Previous Cycle: Risk Category: ☐ Female of Childbeari Risk Category: ☐ Male or Female of no	ng Potential (FCBP) F	≀x va	lid for 7		
*****Ensure Red Blood Cell Phenotype and Delay treatment week(s) CBC & Diff day of treatment Proceed with all medications as written, if greater than or equal to 50 x 109/L, and Dose modification for: Hematology: Proceed with treatment based on blood we	within 96 hours of Day eGFR or creatinine c	1: Al leara _ □	NC grea nce as <sub>l</sub>	ter than or e per protocol r Toxicity: _	equal to 1.0 x 10 <sup>9</sup> /L, platelets
LENALIDOMIDE One cycle = 28 days  ■ Per physician's clinical judgement, physicia daily  □ lenalidomide*mg PO daily, in □ lenalidomide*mg PO	the evening, on Days	1 to 2	:1 and of	ff for 7 days	Pharmacy Use for Lenalidomide dispensing: Part Fill # 1 RevAid confirmation number: Lenalidomide lot number: Pharmacist counsel (initial):
MITTE: (*available as 25 mg, 20mg, 15 m *Note: Use one capsule strength for the to is per capsule and not weight based  FCBP dispense 21 capsules (1 cycle) For Male and Female NCBP: Mitte:capsules orc Pharmacy to dispense one cycle at a time	ng, 10 mg, 5 mg and 2.5 otal dose; there are cos ycles. Maximum 63 cap e, maximum 3 cycles if	5 mg t imp osule: neede	capsules lications s (3 cycled	es).	Part Fill # 2 RevAid confirmation number:  Lenalidomide lot number:  Pharmacist counsel (initial):  Part Fill # 3 RevAid confirmation number:  Lenalidomide lot number:  Pharmacist counsel (initial):
Physician to ensure DVT prophylaxis in molecular weight heparin, ☐ direct orange of the molecular weight heparin, ☐ direct orange or molecular weight heparin weight					
DOCTOR'S SIGNATURE:					SIGNATURE:
Physician Revaid ID:					UC:



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <a href="https://www.bccancer.bc.ca">www.bccancer.bc.ca</a> and according to acceptable standards of care

## PROTOCOL CODE: MYDARLD (subcut)

(Page 2 of 4)

DATE:						
CYCLOPHOSPHAMIDE – Cycles 1 to 8 ( Cycle 9 onwards optional)						
cyclophosphamide 500 mg PO once weekly in the morning on Days 1, 8, 15, and 22. Dispense cycles.						
OR  cyclophosphamide mg PO once weekly in the morning on Days Dispensions OR	se cycles.					
cyclophosphamide 50 mg PO once in the morning every 2 days for doses. Dispense	cycles.					
STEROID (select one)* RN to use patient's therapeutic steroid (if applicable) as pre-med for o	daratumumab -					
☐ <b>dexamethasone</b> ☐ <b>40 mg</b> or ☐ <b>20 mg</b> PO once weekly on Days 1, 8, 15 and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning <i>x</i> doses <u>OR</u> number of 28 day cycles						
dexamethasonemg PO once weekly on Days 1, 8, 15 and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning x doses OR number of 28 day cycles  OR						
predniSONEmg PO once weekly on Days 1, 8, 15 and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning x doses <u>OR</u> number of 28 day cycles						
☐ No Steroid						
*Refer to Protocol for suggested dosing options						
DOCTOR'S SIGNATURE:	SIGNATURE: UC:					



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <a href="www.bccancer.bc.ca">www.bccancer.bc.ca</a> and according to acceptable standards of care

## PROTOCOL CODE: MYDARLD (subcut)

(Page 3 of 4)

DATE:						
**Have Hypersensitivity Reaction Tray and Protocol Available** Insert a peripheral IV and saline lock for Cycle 1 Day 1 only for use in the event of a hypersensitivity reaction.						
DARATUMUMAB	<u> </u>					
Per physician's clinical judgement, physician to ensure prophylaxis with valACYclovir 500 mg PO daily						
DARATUMUMAB PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm						
dexamethasone as ordered in steroid section						
montelukast 10 mg PO prior to daratumumab on Cycle 1 Day 1						
montelukast 10 mg PO prior to each daratumumab						
acetaminophen 650 mg PO prior to each daratumumab. Repeat acetaminophen 650 mg PO every 4 hours when needed						
Select one of the following:						
☐ <b>Ioratadine 10 mg</b> PO prior to each daratumumab, then <b>diphenhydrAMINE 50 mg</b> IV every 4 hours when needed						
OR						
☐ <b>diphenhydrAMINE 50 mg</b> ☐ PO or ☐ IV prior to each daratumumab. Repeat <b>diphenhydrAMINE 50 mg</b> IV every 4 hours when needed						
DARATUMUMAB						
☐ CYCLE # 1, Days 1, 8, 15 and 22:						
daratumumab subcut 1800 mg (fixed dose in 15 mL) subcutaneously into abdomen over 5 min	utes*					
☐ CYCLE # 2, Days 1, 8, 15 and 22: daratumumab subcut 1800 mg (fixed dose in 15 mL) subcutaneously into abdomen over 5 minutes*						
☐ CYCLES 3 to 6, Days 1 and 15:						
daratumumab subcut 1800 mg (fixed dose in 15 mL) subcutaneously into abdomen over 5 minutes*						
, ,	_ cycle(s) (max 2 cycles)					
□CYCLE 7 onwards, Day 1:						
daratumumab subcut 1800 mg (fixed dose in 15 mL) subcutaneously into abdomen over 5 min	utes*					
x	_ cycle(s) (max 3 cycles)					
*Observe patient for 1 hour after administration on Day 1 of Cycle 1 only. For patients switching from IV daratumumab, observe for 30 minutes after the first subcutaneous dose. Observation not required on subsequent doses unless requested by physician. Vital signs immediately prior to and at the end of injection, and at end of observation period of first injection only, and as needed.						
NB: During treatment with subcutaneous daratumumab, administer other subcutaneous drugs at alternative in possible	njection sites whenever					
DOCTOR'S SIGNATURE:	SIGNATURE:					
	UC:					



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <a href="www.bccancer.bc.ca">www.bccancer.bc.ca</a> and according to acceptable standards of care

## PROTOCOL CODE: MYDARLD (subcut)

(Page 4 of 4)

DATE:					
RETURN APPOINTMENT ORDERS					
For Cycles 1 and 2, book chemo on Days 1, 8, 15 and 22					
For Cycles 3 to 6, book chemo on Days 1 and 15					
For Cycle 7 onwards, book chemo on Day 1					
Return in <u>four</u> weeks for Doctor and Cycle					
Return in <u>eight</u> weeks for Doctor and Cycles and Book chemo x 2 cycles.					
Return in twelve weeks for Doctor and Cycles, and Book					
chemo x 3 cycles					
Last Cycle. Return in week(s).					
CBC & Diff, creatinine, urea, sodium, potassium, total bilirubin, ALT, alkaline phosphatase, calcium, albumin, LDH, random glucose, serum protein electrophoresis <u>and</u> serum free light chain levels every 4 weeks					
TSH every three months (i.e. prior to Cycles 4, 7, 10, 13, 16 etc)					
☐ Urine protein electrophoresis every 4 weeks					
☐ Immunoglobulin panel (IgA, IgG, IgM) every 4 weeks					
☐ Beta-2 microglobulin every 4 weeks					
☐ <b>CBC &amp; Diff</b> Days 8, 15, 22					
☐ Creatinine, sodium, potassium Days 8, 15, 22					
☐ Total bilirubin, ALT, alkaline phosphatase Days 8, 15, 22					
☐ Random glucose Days 8, 15, 22					
☐ Calcium, albumin Days 8, 15, 22					
Quantitative beta-hCG blood test for FCBP 7-14 days and 24 h prior to cycle 1 and every week for 4 weeks during cycle 1					
Quantitative beta- hCG blood test for FCBP, every 4 weeks, less than or equal to 7 days prior to the next cycle					
☐ HBV viral load prior to next cycle					
☐ See general orders sheet for additional requests					
Other tests:					
Consults:					
DOCTOR'S SIGNATURE:	SIGNATURE:				
	UC:				